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Abstract
Thyroid cancer is a comparatively rare tumor, which affects 1–5% of women and approxi-
mately 2% of men, although it is the most common endocrine malignancy worldwide. 
Furthermore, the incidence of thyroid cancer has been increasing remarkably in the last 
decades. Currently, diagnosis of thyroid cancer mainly is based on cytological criteria. 
Although fine needle aspiration is a minimally invasive procedure, complications can 
occur. Correct diagnosis is mandatory to select patients for surgical intervention and to 
determine appropriate extent of operation. Overdiagnosis and the associated unneces-
sary surgery should be avoided as it might also lead to complications. Therefore it is 
important to practice noninvasive methods not only for early diagnosis of thyroid cancer 
but also for estimation of prognosis. Liquid biopsy is a promising, noninvasive method 
that can provide detection of circulating tumor cells (CTCs) as well as circulating nucleic 
acids such as DNA, mRNA, and microRNA in a blood sample. The aim of the chapter is 
to highlight the efficacy of liquid biopsy for diagnosis and prognosis of thyroid cancer. 
The chapter will represent a comprehensive literature review based on recent PubMed 
publications (mainly 2012–2018).
Keywords: thyroid carcinoma, early diagnostics, molecular diagnostics, liquid biopsy, 
circulating tumor cells, circulating free DNA, circulating miRNA
1. Introduction
Thyroid cancer is relatively infrequent malignancy, which accounts for about 1–5% of the can-
cer cases in women and less than 2% in men [1]. Although, it is one of the most common can-
cer among endocrine malignancies accounting for more than 95% of new cases in the United 
States [2, 3], according to American Cancer Society, thyroid cancer in the United States in 2019 
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is estimated to be about 53,070 new cases (40,260 in men and 37,810 in woman), and more than 
2000 people will die from the disease [3]. As well as in the rest of the world, the incidence of 
thyroid cancer has increased threefold over the past 30 years and is expected to increase by 
50–60% between 2010 and 2020 [3–5]. The increase in thyroid cancer incidence rates could 
be explained by thyroid ultrasound screening with improved technical performance of the 
equipment, as well as better access to medical examination [1, 6].
Although, there are no significant rise in thyroid cancer mortality rates, growing detection 
of indolent forms may lead to overtreatment of the patients by performing unnecessary 
thyroidectomies [7]. General postoperative complications, such as fever, hemorrhages, infec-
tion, or cardiopulmonary and thromboembolic events, as well as specific complicationssuch 
as hypoparathyroidism/hypocalcemia and vocal cord/fold paralysis can be seen. In large 
population-based study, 27,912 patients were included and analyzed. General postoperative 
complications were observed in 6.5% of the patients and surgery-specific complications in 
12.3% [8]. The diagnostic gold standard for thyroid cancer is the evaluation of histological 
features, although there still are some differential diagnostic difficulties. To avoid complica-
tions, a new, more precise diagnostic tool is necessary to diagnose and manage thyroid cancer 
patients.
Liquid biopsy is a usual blood sampling method, referred to as a noninvasive procedure to 
detect components of the tumor which circulates in the bloodstream, for example, circulating 
tumor cells (CTCs), cell-free nucleic acids, exosomes, or tumor-educated platelets (TEPs); thus 
it can be a promising method in tumor diagnostics prior to surgery, as well as in monitoring 
of the disease [9].
2. Detection of specific particles by liquid biopsy
As previously mentioned, in liquid biopsy, circulating tumor cells (CTC), cell-free nucleic 
acids, exosomes, or tumor-educated platelets (TEPs) can be acquired and studied for different 
purposes [9, 10].
Circulating tumor cells are cells which detaches from primary tumor and deposits in a patient’s 
blood. The described ability of CTC is particularly important to fully understand metastatic 
process; therefore a large scientific research field on this topic has evolved. It is believed that 
CTC can survive in the bloodstream because of the undergoing epithelial-mesenchymal tran-
sition (EMT). In this process tumor cells gain plasticity and motility which allows to extrava-
sate from primary tumor into blood and intravasate into distant tissues as well. Detection of 
CTC can give valuable clinical information about patient’s medical status—CTC can be used 
as a prognostic marker in different carcinomas including malignant thyroid tumors. Analysis 
of these cells can serve in treatment process as well—response to different pharmaceutical 
drugs in individual patient can be analyzed [9, 10].
Circulating cell-free nucleic acids (cfDNA, cfRNA, and cfmiRNA) discharge from apoptotic 
and necrotic tumor cells into the bloodstream. cfDNA originates not only form tumor cells but 
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also from non-tumor cells after exercise, trauma, or inflammation [10]. Extraction of circulat-
ing tumor DNA (ctDNA) alone is a difficult process; therefore mutation in cfDNA particles 
is being searched and indicates the presence of tumor. A lot of mutation has been analyzed 
in different types of tumors, for example, epidermal growth factor receptor mutation in non-
small cell lung cancer. At present, it is the only liquid biopsy test that has granted and has 
FDA approval [9, 11].
By liquid biopsy, cfRNA can be analyzed but this particle is not as stable as cfDNA, therefore 
it is harder to investigate. Another circulating cell-free nucleic acid—microRNAs—is a new 
and more stable tumor marker in the blood. Exosomes are microvesicles (40–150 nm) that 
are released in the blood from tumors and normal cells as well. Exosomes contain proteins, 
DNA, RNA, miRNA, lipids, and metabolites. Tumor-educated platelets (TEPs) are anucle-
ated cell fragments that can be educated by the transfer of tumor-associated particles, mostly 
RNA [9, 10].
3. Papillary thyroid cancer and liquid biopsy
The large increase in the incidence of thyroid cancer is seen in papillary thyroid cancer (PTC) 
which represents the major histological type [12]. PTC accounts for 85% of thyroid malignancy 
[13]. World Health Organization has defined PTC as a malignant epithelial tumor showing 
follicular cell differentiation and a specific signs of nuclear features which include nuclear 
enlargement and overlapping, irregular nuclear contours, and nuclear pseudoinclusions or 
nuclear grooves, as well as optically clear nuclei [14]. PTC measuring 1 cm or smaller in the 
greatest dimension is defined as papillary thyroid microcarcinoma (PTMC). It is suggested 
that incidence of PTC increased largely due to an increase in the incidence of PTMC, probably 
due to thyroid ultrasound screening with improved technical performance of the equipment, 
as well as better access to medical examination. Foci of PTMC have been reported in up to 22% 
of surgical thyroid specimens and up to 36% of autopsy series [6, 15].
The main therapeutic method which is used after the diagnosis of PTC is a total of subtotal 
thyroidectomy with or without radioactive iodine (RAI) and thyroid hormone suppression. 
Afterward monitorization of disease status is necessary for all the PTC patients which is car-
ried out by measuring levels of serum thyroid-stimulating hormone (TSH) and serum thy-
roglobulin (Tg) in the blood. Neck ultrasonography is also performed to detect persistent or 
recurrent PTC nodules in the thyroid gland after treatment [16]. However, if thyroglobulin 
antibodies (TgAb) are found in the blood, serum thyroglobulin could not be used as a reli-
able tumor marker because of false negative rate. Furthermore, long time period is needed 
to observe the changes in the levels of serum TgAb, and this may lead to late diagnosis [17]. 
Therefore, other biomarkers need to be discovered and used to monitor persistent or recur-
rent disease.
A new diagnostic tool—liquid biopsy—can be used to analyze circulating tumor cells (CTCs) 
or circulating epithelial cells (CECs) and circulating cell-free tumor DNA (ctDNA) in the blood 
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of thyroid cancer patients. This minimally invasive diagnostic method has received a lot of 
attention over the past years and can also be used to analyze thyroid cancer patients [18]. 
However, in the case of thyroid carcinoma, only a few studies have been exploring the sig-
nificance of CTCs in the blood. CTCs are malignant epithelial cells which can separate from 
primary tumor, invade blood and lymph vessels, and travel through the body to form distant 
metastases [19]. Salvianti with colleagues proved that quantity of cfDNA with integrity index 
180/67 in thyroid cancer patients was higher than in those who had benign thyroid nodules. 
Therefore, cfDNA could be a suitable marker to diagnose thyroid cancer [20]. On the surface of 
CTC, epithelial cell adhesion molecule (EpCAM) is found in overexpressed state and therefore 
can be used for malignant cell visualization from a sample taken by liquid biopsy. Usually 
EpCAM is overexpressed on tumor cells. The visualization of CTCs can be performed with 
different antibodies, which allows visualize cells under a fluorescence microscope. In other 
studies, quantification of various messenger RNAs (mRNAs) is detected in the blood [19].
Not only mRNA but also microRNA could be detected in CTCs [21]. Biochemical altera-
tions of cancer cells are largely supported by noncoding RNA (ncRNA) dysregulation in the 
tumor site. Noncoding RNAs lack an open reading frame and do not have protein-coding 
ability. Based on the size of the functional RNA molecule, regulatory ncRNAs are classified 
as long ncRNAs and small ncRNAs or microRNA (miRNA) [22]. miRNAs are small, evolu-
tionary conserved, single-stranded, noncoding RNA molecules (approximately 22 nucleo-
tides in length) that bind target mRNA to regulate gene expression [23, 24]. MicroRNAs 
are involved in various physiological and pathological functions, such as apoptosis, cell 
proliferation, and differentiation, which indicate their functionality in carcinogenesis as 
tumor suppressor genes or oncogenes [25]. Up- or downregulation of miRNA can influence 
the tumorigenic outcome depending on the role(s) of the target genes on vital signaling 
processes [26].
The most often upregulated miRNAs in papillary thyroid cancer (PTC) are miR-146b, miR-
222, miR-221, and miR-181b. Overexpressed miR-146b targets retinoic acid receptor beta 
(RARβ) and causes reduced expression of this gene leading to increased tumor aggres-
siveness and extrathyroidal invasion. miR-221 and miR-222 target tumor suppressor and 
cell-cycle regulator p27. Reduced expression of p27 results in increased proliferation of 
tumor cells. These processes are related to aggressive behavior of tumor, extrathyroidal 
invasion, and the presence of lymph node invasion [21, 27–29]. miR-181b also is over-
expressed in PTC compared to normal thyroid tissue. miR-181b inhibits expression of 
cylindromatosis (CYLD) gene which acts as tumor suppressor and normally induces cel-
lular apoptosis [28, 30].
The most often downregulated miRNAs in PTC are miR-145, miR-451, miR-613, and miR-
137. miR-145 acts a tumor suppressor in thyroid cancer, and downregulation leads to cancer 
growth through several pathways [28]. miR-451 acts as a tumor suppressor by targeting the 
PI3/AKT pathway. Downregulation of miR-451a is associated with tumor aggressiveness and 
the presence of extrathyroidal invasion [27, 28]. miR-613 is involved in PTC cell proliferation 
and invasion [28, 29]. In PTC, miR-137 expression is downregulated leading to increased cel-
lular proliferation, invasion, and migration [28] (Table 1).
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4. Follicular thyroid cancer and liquid biopsy
Follicular thyroid carcinoma (FTC) is the second most common type of thyroid cancer, com-
prising 10–15% of all thyroid carcinomas [4, 13, 31]. Although FTC is the second most common 
type, its incidence has decreased over the past few years [31]. World Health Organization has 
defined FTC as a malignant epithelial tumor showing follicular cell differentiation in which 
the diagnostic nuclear features of PTC are absent. Lesions are usually encapsulated and show 
invasive growth pattern [14]. The diagnosis of FTC is a difficult dilemma in cases when cap-
sular, vascular, or extrathyroidal invasion or metastasizing is not straightforward [32, 33]. A 
lot of studies have researched biomarkers in liquid biopsy for PTC; however, limited amount 
of information is found about FTC. One of those studies explored miRNA dysregulation and 
tried to found miRNA markers for diagnostic purposes in the case of FTC [34]. Dettmer with 
colleagues found upregulation of miR-182/-183/-221/-222/-125a-3p and a downregulation of 
miR-542-5p/-574-3p/-455/-199a. They concluded that distinction between FTC and hyperplas-
tic nodules can be done by the use of dysregulated miRNA in the tissues. The miRNAs found 
Diagnosis Type of 
miRNA
Type of regulation Outcome References
Papillary 
thyroid cancer
miR-146b Upregulated in cells Aggressive behavior and 
extrathyroidal invasion
Rossi et al. [21]
Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
Chruscik et al. [29]
miR-222 Upregulated in cells Aggressive behavior, extrathyroidal 
invasion, and lymph node metastasis
Rossi et al. [21]
Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
Chruscik et al. [29]
miR-221 Upregulated in cells Aggressive behavior, extrathyroidal 
invasion, and lymph node metastasis
Rossi et al. [21]
Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
Chruscik et al. [29]
miR-181b Upregulated in cells Decreased apoptosis of cancer cells Boufraqech et al. [28]
miR-145 Downregulated cells Regulates cancer growth Boufraqech et al. [28]
miR-451 Downregulated cells Tumor aggressiveness Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
miR-613 Downregulated cells Increased cellular proliferation and 
invasion
Boufraqech et al. [28]
Chruscik et al. [29]
miR-137 Downregulated cells Increased cellular proliferation, 
invasion, and migration
Boufraqech et al. [28]
Table 1. Expression of microRNA in PTC.
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in follicular thyroid cancers (FTC) are also frequently present in other subtypes of thyroid 
cancer [27]. miR-199a-5p is downregulated, but miR-197 and miR-346 are upregulated in FTC 
leading to increased cancer cell proliferation [28] (Table 2).
5. Medullary thyroid cancer and liquid biopsy
Medullary thyroid cancer (MTC) accounts for only 5% of thyroid cancers; it is responsible 
for approximately 13% of all thyroid cancer-related deaths [4]. MTC is a malignant thyroid 
tumor showing evidence of C-cell differentiation [14]. One of the recently studied miRNAs 
in medullary thyroid cancer is miR-21, which is downregulated especially in the aggressive 
forms [27]. miR-129-5p also is significantly downregulated in MTC compared to normal tis-
sue leading to increased cellular invasion and migration [28] (Table 3).
Diagnosis Type of 
miRNA
Type of regulation Outcome References
Medullary thyroid 
cancer
miR-183 Upregulated in tissue Aggressive behavior and 
metastatic disease
Rodriguez-Rodero et al. [27]
Accardo et al. [35]
miR-375 Upregulated in tissue Aggressive behavior and 
metastatic disease
Rodriguez-Rodero et al. [27]
Accardo et al. [35]
Boufraqech et al. [28]
miR-21 Downregulated in 
tissue
Aggressive behavior and 
metastatic disease
Rodriguez-Rodero et al. [27]
Accardo et al. [35]
Boufraqech et al. [28]
Pennelli et al. [36]
miR-129-5p Downregulated in 
tissue
Decreased cellular apoptosis 
and increased cell migration
Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
Table 3. Expression of microRNA in MTC.
Diagnosis Type of 
miRNA
Type of regulation Outcome References
Follicular cancer miR-199a-5p Downregulated in cells Increased cellular 
proliferation
Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
miR-197 Upregulated in cells Increased cellular 
proliferation
Rossi et al. [21]
Boufraqech et al. [28]
miR-346 Upregulated in cells Increased cellular 
proliferation
Rossi et al. [21]
Boufraqech et al. [28]
Table 2. Expression of microRNA in FTC.
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6. Anaplastic thyroid cancer and liquid biopsy
Anaplastic thyroid carcinoma (ATC) is aggressive thyroid tumor which consists of undif-
ferentiated follicular thyroid cells [14].
Many miRNAs have been found to be dysregulated in thyroid cancer, but only a few miRNAs 
are exclusively dysregulated in anaplastic thyroid cancer (ATC) [28]. Loss of miR-200 expres-
sion in ATC results in epithelial-mesenchymal transition (EMT) that represses the epithelial 
features of cancer cells and disrupts the cell-cell adhesion mediated by the loss of E-cadherin. 
This process enables cells to migrate and invade [26–28].
Overexpression of the miR-17-92 cluster results in downregulation of tumor suppressor 
PTEN. This process potentiates the activation of AKT/mTOR growth and survival signaling. 
Another important tumor-suppressive pathway targeted by miR-17-92 is the TGFβ signaling 
pathway [28]. Increase of miR-17-92 leads to a loss of the tumor inhibitory effect of TGFβ in 
thyroid cancer cells, which enhances cell proliferation [26–28].
Diagnosis Type of 
miRNA
Type of regulation Outcome References
Anaplastic 
thyroid cancer
miR-30 
family
Downregulated in 
cells
Protect cancer cells from 
apoptosis and autophagy
Sasanakietkul et al. [26]
Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
miR-125a, 
miR-125b
Downregulated in 
cells
Promote tumor invasion Sasanakietkul et al. [26]
miR-138 Downregulated in 
cells
Increase with the 
progression of histological 
dedifferentiation and 
malignant behavior
Sasanakietkul et al. [26]
Rodriguez-Rodero et al. [27]
miR-200 
family
Downregulated in 
cells
Increase the invasive 
potential of tumor
Sasanakietkul et al. [26]
Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
miR-17-92 
cluster
Upregulated in cells Promote tumor growth and 
invasion
Sasanakietkul et al. [26]
Rodriguez-Rodero et al. [27]
Boufraqech et al. [28]
miR-146a, 
miR-146b
Upregulated in cells Dysregulated cell 
differentiation and invasion
Rodriguez-Rodero et al. [27]
Sasanakietkul et al. [26]
miR-221, 
miR-222
Upregulated in cells Promote tumor growth and 
invasion
Rodriguez-Rodero et al. [27]
Sasanakietkul et al. [26]
miR-4295 Upregulated in cells Increased cell migration and 
invasion
Rodriguez-Rodero et al. [27]
Sasanakietkul et al. [26]
Table 4. Expression of microRNA in ATC.
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miR-30 plays a role in thyroid cancer differentiation and progression. Overexpression of miR-
30 family members leads to a change in cell morphology and decreased vimentin expression 
in cancer cells [28]. This is suggesting that miR-30 family members are involved in cancer 
progression by regulating the EMT process [26–28] (Table 4).
7. Poorly differentiated thyroid cancer and liquid biopsy
Poorly differentiated thyroid carcinoma (PDTC) is malignant epithelial cell tumor derived 
from follicular cells that shows limited characteristics of follicular cell differentiation and is 
morphologically and behaviorally intermediate between differentiated thyroid carcinomas 
and anaplastic thyroid carcinoma [14]. miR-23 and miR-150 are downregulated, but miR-
146b, miR-221, and miR-222 are upregulated in poorly differentiated thyroid cancer ensuring 
more aggressive behavior (Table 5).
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